Menopause

Menopause is the permanent cessation of menstrual periods for 12 consecutive months, signaling the end of ovarian reproductive function. The average age in the United States is 51, with a normal range of 45–55. It is not a single event but the conclusion of a biological transition that begins years earlier and whose consequences extend for decades. The drop in ovarian estrogen triggers a wide spectrum of symptoms—from hot flashes and sleep disruption to vaginal atrophy and bone loss—and reshapes long-term cardiovascular and metabolic risk. Management now spans hormone therapy, targeted non-hormonal medications, local vaginal treatments, and lifestyle strategies. Understanding the full picture across all stages is the first step toward informed, personalized care.

Table of Contents

1. Perimenopausal Transition
2. Vasomotor Symptoms (Hot Flashes)
3. Genitourinary Syndrome of Menopause
4. Bone Health and Osteoporosis
5. Cardiovascular Risk After Menopause
6. Mood, Sleep, and Cognitive Symptoms
7. Hormone Therapy: Benefits and Indications
8. Hormone Therapy: Risks and Contraindications
9. Non-Hormonal Treatments
10. Lifestyle and Long-Term Health
11. Key Research Papers
12. Connections
13. Featured Videos

Perimenopausal Transition

Perimenopause is the transition phase that typically begins 4–8 years before the final menstrual period, usually in the mid-to-late 40s. It is driven by the accelerating depletion of ovarian follicles and the resulting variability in estrogen and progesterone production.

What Changes in the Cycle

Cycles may shorten or lengthen, ovulation becomes irregular, and anovulatory cycles (no ovulation) become more frequent. Women may experience oligomenorrhea (infrequent periods), spotting between periods, or sudden heavier flow. These changes reflect fluctuating, often transiently elevated estrogen followed by sharp drops rather than a simple linear decline.

Hormonal Markers

Anti-Müllerian hormone (AMH) falls as the ovarian reserve shrinks and is the earliest measurable signal of declining follicular reserve. Follicle-stimulating hormone (FSH) begins to rise as the pituitary receives less negative feedback from inhibin B and estradiol. However, a single elevated FSH does not confirm menopause during perimenopause: FSH fluctuates dramatically cycle to cycle, and estrogen can still spike unpredictably. The clinical definition of natural menopause requires 12 consecutive months of amenorrhea.

Fertility in Perimenopause

Ovulation remains possible until the final period. Pregnancy can and does occur during perimenopause. Women who do not wish to conceive should continue reliable contraception until they have reached 12 months of amenorrhea (the postmenopause threshold). Stopping contraception prematurely based on symptoms alone carries real pregnancy risk.

Types of Menopause

• Natural menopause — 12 consecutive months of amenorrhea occurring between ages 45 and 55 (average 51 in the US), driven by natural follicular depletion.
• Premature menopause / Primary Ovarian Insufficiency (POI) — Ovarian failure before age 40, affecting approximately 1% of women. Causes include idiopathic depletion, Turner syndrome mosaicism, chemotherapy, pelvic radiation, and autoimmune destruction of follicles. POI carries longer exposure to estrogen deficiency and requires particular urgency around hormone therapy to protect bone and cardiovascular health.
• Early menopause — Occurring between ages 40 and 45; same long-term risks as POI but somewhat less severe.
• Surgical menopause — Bilateral oophorectomy (removal of both ovaries) causes immediate, abrupt menopause regardless of age. Symptoms are typically more severe than natural menopause because the hormonal drop is instantaneous rather than gradual, and the woman may be decades younger than average menopause age.

Back to Table of Contents

Vasomotor Symptoms (Hot Flashes)

Hot flashes are the hallmark symptom of menopause, affecting approximately 75–80% of women. They are sudden waves of intense heat felt across the face, neck, and chest, followed by sweating and often a chill as the body overcorrects. Individual episodes last 1–5 minutes. Severe cases involve 7–10 or more episodes per day. Nocturnal hot flashes (night sweats) repeatedly wake women from sleep, producing a cascade of daytime fatigue, irritability, and cognitive impairment.

Mechanism

Estrogen withdrawal narrows the thermoregulatory neutral zone in the hypothalamus: the band of core temperatures the brain tolerates without triggering cooling or heating responses becomes so narrow that trivial fluctuations trigger a full hot flash. The NKB–NK3R pathway is central to this process. Neurokinin B (NKB), released by KNDy neurons in the hypothalamic arcuate nucleus, activates NK3 receptors that drive both GnRH/LH surges and thermoregulatory centers. In the absence of estrogen, NKB signaling is upregulated and unchecked—directly explaining why NK3R antagonists (such as fezolinetant) effectively reduce hot flashes without touching estrogen.

Duration

The older teaching that hot flashes last “a few months” is wrong. The Study of Women’s Health Across the Nation (SWAN) found median vasomotor symptom duration of 7.4 years, with women who began symptoms during early perimenopause experiencing the longest duration (a median of 11.8 years). Some women continue to have hot flashes into their 70s and 80s. Earlier onset predicts longer total burden.

Back to Table of Contents

Genitourinary Syndrome of Menopause (GSM)

GSM replaces the older, stigmatizing terms “vaginal atrophy” and “atrophic vaginitis.” The vagina, vulva, bladder, and urethra all contain estrogen receptors and depend on estrogen to maintain their structure and function. As estrogen falls, these tissues thin, lose elasticity, and become more vulnerable to irritation and infection.

Symptoms

• Vaginal dryness — the most common complaint, affecting over 50% of postmenopausal women.
• Dyspareunia — painful intercourse. Affects 50% of postmenopausal women at some point; profoundly impacts quality of life and intimate relationships. Among the most undertreated conditions in women’s health.
• Vaginal burning and irritation — often mistaken for a yeast infection.
• Urinary urgency and frequency — from urethral and bladder trigone atrophy.
• Recurrent urinary tract infections (UTIs) — rising vaginal pH (above 4.5, versus the protective premenopausal pH of 3.5–4.5) disrupts the lactobacillus-dominant microbiome and permits pathogen colonization.
• Urge incontinence — related to loss of urethral support and tissue integrity.

Critical Distinction

Unlike hot flashes, which often diminish over time, GSM is progressive. It worsens year by year without treatment. Vaginal epithelium thins, the introitus narrows, and the pH destabilizes further. Treatment initiated early preserves more tissue than treatment started after years of atrophy. Women and clinicians frequently avoid discussing dyspareunia—this silence is a major driver of preventable suffering.

Back to Table of Contents

Bone Health and Osteoporosis

Bone loss accelerates dramatically in the years immediately following menopause. The rate jumps from the premenopausal 0.3–0.5% per year to 2–3% per year for the first 5–10 years after the final period, driven directly by estrogen loss.

Mechanism

Estrogen normally suppresses osteoclast activity (the cells that resorb bone) by promoting osteoclast apoptosis and reducing RANKL signaling. When estrogen falls, osteoclasts become overactive while osteoblast activity (bone formation) does not compensate proportionally. The result is a net loss of bone mineral density (BMD), with trabecular (spongy) bone—which predominates in vertebrae and the femoral neck—most vulnerable.

Screening and Diagnosis

Dual-energy X-ray absorptiometry (DXA) is the gold standard for measuring BMD. The US Preventive Services Task Force recommends screening at age 65, or earlier for women with risk factors (premature or surgical menopause, family history, low body weight, smoking, corticosteroid use). A T-score of −2.5 or below defines osteoporosis; −1.0 to −2.5 defines osteopenia. The FRAX calculator integrates BMD with clinical risk factors to estimate 10-year fracture probability and guide treatment decisions.

Consequences

Hip fractures carry a one-year mortality approaching 20–30% in older women and confer significant permanent functional impairment. Vertebral fractures cause chronic pain, height loss, and kyphosis. Wrist fractures are common at younger postmenopausal ages. Prevention beginning at or near menopause—through hormone therapy, calcium, vitamin D, and appropriate pharmacotherapy when indicated—substantially reduces lifetime fracture burden.

Back to Table of Contents

Cardiovascular Risk After Menopause

Cardiovascular disease (CVD) is the leading cause of death in postmenopausal women—a fact that often surprises patients, who tend to fear breast cancer more. Premenopausal women have substantially lower CVD risk than age-matched men, a protection attributable in large part to estrogen.

How Estrogen Protects the Heart and Vessels

• Promotes vasodilation through nitric oxide upregulation and direct smooth-muscle relaxation.
• Has anti-inflammatory effects on endothelium, slowing atherosclerotic plaque formation.
• Maintains a favorable lipid profile: higher HDL cholesterol, lower LDL cholesterol, lower triglycerides.
• Improves insulin sensitivity.

Postmenopausal Cardiovascular Changes

• Lipid changes — LDL rises, HDL falls, and triglycerides increase, together shifting the lipoprotein profile toward atherogenesis.
• Blood pressure — tends to rise postmenopausally through mechanisms including the renin–angiotensin–aldosterone system and increased sympathetic tone.
• Visceral fat accumulation — fat distribution shifts from a gynecoid (hip/thigh) to an android (abdominal) pattern, increasing metabolic syndrome risk.
• Endothelial dysfunction — progressive loss of vascular compliance accelerates atherosclerosis.

Lifestyle Is First-Line

The Mediterranean dietary pattern (high in olive oil, vegetables, legumes, fish, and whole grains; low in processed foods and red meat) reduces cardiovascular events by approximately 25–30% in women. Regular aerobic exercise (150 minutes of moderate-intensity per week), smoking cessation, and weight management are foundational and have additive benefits. Statin therapy is appropriate when LDL meets guideline thresholds for primary prevention.

Back to Table of Contents

Mood, Sleep, and Cognitive Symptoms

Sleep Disruption

Night sweats directly fragment sleep by waking women multiple times per night. Beyond that, estrogen and progesterone have independent effects on sleep architecture: estrogen promotes REM sleep and reduces sleep-onset latency; progesterone has anxiolytic and sedating properties. Their loss produces insomnia that persists even in the absence of night sweats. Sleep-disordered breathing (obstructive sleep apnea) also increases postmenopausally, partly due to weight changes and loss of upper airway muscle tone.

Mood and Depression

Perimenopause is a period of elevated vulnerability to depression, even in women with no prior psychiatric history. The Seattle Midlife Women’s Health Study and the Penn Ovarian Aging Study both documented substantially higher rates of depressive symptoms during the perimenopausal transition. The mechanism involves estrogen’s role in serotonin and norepinephrine regulation in limbic circuits. Treatment options include SSRIs or SNRIs (which also address hot flashes), and hormone therapy itself has demonstrated antidepressant effects during the perimenopausal transition (though it is less clearly effective for established postmenopausal depression without active vasomotor symptoms).

Cognitive Changes

Many women report subjective memory complaints, word-finding difficulty, and “brain fog” during perimenopause and early postmenopause. Estrogen receptors are abundant in the hippocampus and prefrontal cortex and modulate acetylcholine systems critical for memory consolidation. Whether menopause causes lasting cognitive impairment beyond the aging process remains debated. WHIMS (Women’s Health Initiative Memory Study) found cognitive harm in the older WHI cohort but this population was 65+ and starting HRT a decade or more after menopause—not representative of the typical menopausal woman. Observational data from younger initiators suggest possible neuroprotection.

Sexual Dysfunction

Reduced libido is multifactorial at menopause: testosterone declines (ovaries produce approximately 50% of testosterone), dyspareunia from GSM makes sex painful, fatigue from sleep disruption reduces desire, and mood changes affect intimacy. Each contributing factor has a specific treatment target. Addressing GSM (local estrogen or ospemifene), treating depression, and considering testosterone supplementation together are more effective than any single intervention.

Back to Table of Contents

Hormone Therapy: Benefits and Indications

Menopausal hormone therapy (MHT or HRT) replaces declining ovarian hormones and is the most effective available treatment for vasomotor symptoms and GSM. It also provides clinically meaningful benefits for bone, mood, sleep, sexual function, and—when started early—possibly cardiovascular health.

The WHI Reappraisal and the Timing Hypothesis

The 2002 Women’s Health Initiative (WHI) results initially triggered mass discontinuation of HRT after reporting increased breast cancer, coronary events, stroke, and VTE. But critical problems with that interpretation were subsequently identified: the mean participant age was 63—ten or more years past menopause—and the regimen used (oral conjugated equine estrogen plus medroxyprogesterone acetate, a synthetic progestin) differs substantially from modern transdermal estradiol with micronized progesterone. Re-analyses stratified by age revealed that women aged 50–59 at enrollment had reduced coronary events and overall mortality.

The current consensus among The Menopause Society, the International Menopause Society, and the British Menopause Society is that for healthy women under age 60 or within 10 years of menopause onset, the benefits of HRT clearly outweigh the risks for most women—the “timing hypothesis” or “window of opportunity.”

What HRT Typically Contains

• Estrogen (estradiol) — the primary active component for symptom relief; bioidentical estradiol (17β-estradiol) is now the standard in most modern regimens.
• Progestogen (for women with a uterus) — required to protect the endometrium from estrogen-induced hyperplasia and cancer. Women who have had a hysterectomy can safely take estrogen alone. The preferred progestogen is micronized progesterone (Prometrium in the US; Utrogestan in the UK), a bioidentical compound with a safer cardiovascular and breast profile than synthetic progestins.

Key Benefits

• Vasomotor symptoms — 75–90% reduction in hot flash frequency and severity; the most effective available treatment by a wide margin.
• GSM — estrogen restores vaginal epithelium, normalizes pH, resolves dryness and dyspareunia, and reduces recurrent UTIs. Systemic HRT addresses GSM; local vaginal estrogen addresses GSM with negligible systemic absorption.
• Bone protection — MHT prevents postmenopausal bone loss and reduces fractures by approximately 25–40% (WHI data).
• Cardiovascular (timing-dependent) — when started within 10 years of menopause, associated with reduced coronary events in WHI re-analyses and in the Danish Osteoporosis Prevention Study (DOPS).
• Mood and sleep — improved sleep quality (partially via elimination of night sweats; partially direct effects); reduced depressive symptoms in perimenopausal women.
• Type 2 diabetes — approximately 20–30% reduction in incident diabetes in MHT users across multiple studies.
• Quality of life — consistently improved across validated instruments.

Indications

• Moderate-to-severe vasomotor symptoms significantly affecting quality of life.
• GSM not adequately managed by local-only treatment.
• Premature ovarian insufficiency or surgical menopause (strong indication; should continue at minimum until average menopause age of 51).
• Prevention and treatment of postmenopausal osteoporosis in women who are candidates.

Back to Table of Contents

Hormone Therapy: Risks and Contraindications

Breast Cancer

Combined estrogen-plus-progestogen MHT is associated with a small absolute increase in breast cancer risk after approximately 3–5 years of use: roughly 4–8 extra cases per 10,000 women per year of use—comparable in magnitude to the risk added by daily alcohol consumption or obesity. By contrast, estrogen-only MHT in the WHI was associated with a reduced risk of breast cancer in women without a uterus.

Micronized progesterone (bioidentical) appears to carry meaningfully lower breast cancer risk than synthetic progestins (medroxyprogesterone acetate), based on the E3N French cohort study and mechanistic differences in progesterone receptor binding. This is why most contemporary European and Australian guidelines prefer micronized progesterone over synthetic progestins when a progestogen is required.

For women with BRCA1/BRCA2 mutations, the decision about HRT after risk-reducing oophorectomy is individualized; short-term HRT until average menopause age is generally supported by expert consensus given the severity of surgical menopause consequences.

Venous Thromboembolism (VTE)

Oral estrogen increases VTE risk approximately 2–3-fold over baseline (from roughly 1–2 per 1000 per year to 2–4 per 1000 per year in low-risk women). Transdermal estrogen does not increase VTE risk—because it bypasses hepatic first-pass metabolism and does not activate coagulation factor synthesis. Transdermal estrogen is therefore strongly preferred in any woman with elevated VTE risk (obesity, personal or family history, known thrombophilia, prolonged immobility).

Stroke

Oral estrogen is associated with a modest increase in ischemic stroke risk, particularly in older postmenopausal women and at higher oral doses. Transdermal estrogen at standard doses does not appear to carry this risk in observational data.

Contraindications

• Absolute: Active or recent breast cancer; unexplained vaginal bleeding; active venous thromboembolism; active coronary heart disease or recent myocardial infarction; active liver disease with impaired hepatic metabolism.
• Relative (individualized decision): Personal history of estrogen-sensitive cancers (endometrial, breast); history of VTE (transdermal routes may be acceptable); migraine with aura (avoid oral estrogen; consider transdermal); uncontrolled hypertension; active gallbladder disease.

Back to Table of Contents

Non-Hormonal Treatments

For Vasomotor Symptoms

• Fezolinetant (Veozah) — FDA-approved in May 2023; the first non-hormonal drug specifically targeting the menopausal thermoregulatory pathway. An NK3R antagonist, it blocks neurokinin B signaling in the hypothalamic arcuate nucleus, directly quieting the KNDy-neuron–driven hot flash mechanism. Dose: 45 mg daily. In phase 3 trials (SKYLIGHT 1 and 2), it reduced moderate-to-severe hot flash frequency by approximately 60–73% versus placebo at week 4 and maintained this over 52 weeks. First-line non-hormonal option when HRT is contraindicated or declined.
• Paroxetine 7.5 mg (Brisdelle) — the only other FDA-approved non-hormonal treatment specifically for menopausal hot flashes. Works via central serotonin reuptake inhibition. Reduces hot flash frequency by approximately 50–60%. Note: paroxetine inhibits CYP2D6 and should not be combined with tamoxifen (reduces tamoxifen efficacy in breast cancer treatment).
• Other SSRIs/SNRIs (off-label) — escitalopram 10–20 mg, venlafaxine 37.5–150 mg, and desvenlafaxine 50–100 mg all demonstrate 50–60% hot flash reduction in randomized trials and are widely used off-label. Preferred first-line non-hormonal agents when concurrent depression or anxiety is present.
• Gabapentin — 300 mg three times daily (900 mg/day); 54% hot flash reduction in randomized trials. Particularly useful for women with concurrent neuropathic pain or prominent night sweats. Side effects: sedation, dizziness, cognitive dulling.
• Clonidine — alpha-2 adrenergic agonist; approximately 50% hot flash reduction but significant side effects (dry mouth, hypotension, sedation) limit use. A reasonable option when others fail.
• Oxybutynin — anticholinergic; demonstrated hot flash reduction in some studies but cognitive concerns in older women limit use.

For GSM

• Vaginal estrogen (local) — cream, vaginal ring (Estring), or vaginal tablet/insert (Vagifem, Yuvafem). Systemic absorption is minimal at standard doses, making vaginal estrogen safe even for most women with breast cancer history when used at low doses (though oncology consultation is appropriate). Highly effective: restores vaginal epithelium, normalizes pH, resolves dryness, dyspareunia, and urinary symptoms. Does not require a progestogen (even in women with a uterus, because systemic absorption is negligible). The most underutilized effective treatment in women’s health.
• Ospemifene (Osphena) — oral selective estrogen receptor modulator (SERM); FDA-approved for dyspareunia and vulvovaginal atrophy from GSM. Acts as an estrogen agonist in vaginal tissue. Dose: 60 mg daily with food. Appropriate for women who prefer an oral pill over vaginal application.
• Prasterone / intravaginal DHEA (Intrarosa) — FDA-approved vaginal suppository. DHEA is converted locally to estrogen and testosterone in vaginal tissue, restoring epithelial function without meaningful systemic hormone levels. Effective for dyspareunia and GSM.
• Vaginal moisturizers — Replens, Hyalofemme, and similar products (hyaluronic acid or polycarbophil base) applied 3 times per week maintain tissue hydration on an ongoing basis. Non-hormonal maintenance option; distinct from lubricants.
• Lubricants — water-based or silicone-based products provide immediate relief during intercourse. Not a treatment for the underlying atrophy but valuable for symptom management.

Back to Table of Contents

Lifestyle and Long-Term Health

Exercise

Weight-bearing aerobic exercise (walking, jogging, dancing) and resistance training (weights, bands) work together at menopause: aerobic exercise supports cardiovascular health and modest weight management; resistance training preserves muscle mass and bone density (osteoblasts respond to mechanical loading). Target 150 minutes of moderate-intensity aerobic activity per week. Yoga and tai chi have demonstrated modest reductions in hot flash frequency and severity and improve balance and mood.

Nutrition

• Calcium — 1200 mg per day from food and supplements combined in postmenopausal women. Dairy, fortified plant milks, leafy greens, and tinned fish with bones are dietary sources.
• Vitamin D — 800–2000 IU per day; required for calcium absorption and has independent bone effects. Serum 25(OH)D of 40–60 ng/mL is a reasonable target.
• Mediterranean dietary pattern — reduces cardiovascular risk, maintains healthy weight, and may modestly improve hot flash burden.
• Soy isoflavones — weak estrogen-receptor agonists. Meta-analyses show a modest reduction in hot flash frequency (approximately 6–7%) and frequency, with a favorable safety profile. Effect is clinically small but acceptable as a complementary strategy. Soy food (tofu, edamame, miso) is preferable to concentrated supplements.

Weight Management

Visceral fat increases postmenopausally even without caloric excess, driven by hormonal changes in fat distribution signaling. Excess adiposity amplifies cardiovascular risk, worsens sleep apnea, may increase hot flash severity (adipose tissue stores heat), and contributes to metabolic syndrome. Sarcopenic obesity (high fat, low muscle) is a particular postmenopausal risk; combining resistance training with adequate protein intake (1.2–1.6 g/kg/day) addresses both components.

Pelvic Floor Physical Therapy

Pelvic floor physical therapy is evidence-based for urinary incontinence and GSM-related pelvic pain. Pelvic floor exercises (Kegels) performed 3–4 times daily (3 sets of 10–15 contractions) improve stress and urge incontinence. A trained pelvic floor therapist can identify specific dysfunction patterns and apply manual therapy, biofeedback, and dilator protocols for dyspareunia. Substantially underutilized.

Sleep Hygiene

Maintain consistent sleep and wake times, keep the bedroom cool (to minimize hot flash triggering), avoid alcohol and caffeine in the evening (both worsen hot flash frequency and sleep quality), limit screen time before bed, and consider cognitive behavioral therapy for insomnia (CBT-I)—the most effective non-pharmacological insomnia treatment.

Cognitive Engagement and Brain Health

Regular mentally stimulating activity (reading, learning, social engagement) is associated with reduced cognitive decline risk in aging. Exercise has an independent protective effect on hippocampal volume. While the evidence that these interventions specifically counteract menopausal cognitive changes is limited, they are low-risk and align with general brain health recommendations.

Back to Table of Contents

Key Research Papers

1. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013;310(13):1353–1368. doi:10.1001/jama.2013.278040 (PMID: 24084921)
2. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2015;100(11):3975–4011. doi:10.1210/jc.2015-2236 (PMID: 26444994)
3. Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause Society. Menopause. 2014;21(10):1063–1068. doi:10.1097/GME.0000000000000329 (PMID: 25160739)
4. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419–427. doi:10.1016/S0140-6736(03)14065-2 (PMID: 12927427)
5. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159–1168. doi:10.1016/S0140-6736(19)31709-X (PMID: 31474332)
6. Peacock K, Carlson K, Ketvertis KM. Menopause. In: StatPearls. NCBI Bookshelf. PubMed NBK507826 (Updated 2023; continuously updated review)
7. Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Internal Medicine. 2015;175(4):531–539. doi:10.1001/jamainternmed.2014.8063 (PMID: 25686030)
8. Pinkerton JV, Bhupathiraju SN, Manson JE. Menopausal hormone therapy and risk of cardiovascular disease. In: Menopause. UpToDate / Crandall CJ, Mehta JM, Manson JE. Current concepts in the pharmacological treatment of menopause. JAMA. 2023;329(22):1943–1944. doi:10.1001/jama.2023.4959 (PMID: 37129628)
9. Johnson KA, Martin N, Nappi RE, et al. Efficacy and safety of fezolinetant in moderate-to-severe vasomotor symptoms associated with menopause: a phase 3 RCT. Obstetrics & Gynecology. 2023;141(6):1080–1090. doi:10.1097/AOG.0000000000005200 (PMID: 37100644)
10. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–845. doi:10.1161/CIRCULATIONAHA.106.642280 (PMID: 17261659)
11. Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes, Obesity and Metabolism. 2006;8(5):538–554. doi:10.1111/j.1463-1326.2005.00545.x (PMID: 16918589)
12. Soares CN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Archives of General Psychiatry. 2001;58(6):529–534. doi:10.1001/archpsyc.58.6.529 (PMID: 11386980)

PubMed Topic Searches

1. Menopause management
2. Menopausal hormone therapy benefits and risks
3. Genitourinary syndrome of menopause
4. Hot flash treatment menopause
5. Fezolinetant NK3R vasomotor symptoms

Back to Table of Contents

Connections

• Perimenopause
• Menopause & HRT (Deep-Dive)
• Perimenopause Symptom Tracker & Hormonal Testing
• Hot Flashes & Night Sweats
• GSM & Vaginal Estrogen
• Bone Loss Prevention & HRT
• HRT Risks: Breast Cancer, Clots, Stroke
• Non-Hormonal Options (SSRIs, Gabapentin, Fezolinetant)
• Testosterone Therapy for Women
• Estradiol Formulations: Patch, Gel, Oral
• Micronized Progesterone vs Synthetic Progestins
• Osteoporosis
• Cardiovascular Disease
• Depression
• Insomnia
• Anxiety
• Hormone Panel
• Reproductive Medicine

Featured Videos